VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

November 14, 2026

**To**
**The Listing Department**
**National Stock Exchange of India Limited**
**Exchange Plaza, Plot C-1, Block- G**
**Bandra Kurla Complex, Bandra (East)**
**Mumbai – 400051**

**NSE Scrip: VILINBIO**

**Sub: Outcome of Board Meeting held on November 14, 2026**

Dear Sir / Madam

Pursuant to Regulation 33 and other applicable Regulations of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their Meeting held today i.e. Saturday, November 14, 2026, have inter alia, considered, approved and taken on record the following matters:

1. Approved the Unaudited Standalone Financial Results for the half-year ended September 30, 2026 along with Limited Review Report.
2. Approved the Unaudited Consolidated Financial Results for the half-year ended September 30, 2026 along with Limited Review Report.
3. Approved the Statement of Deviation regarding the utilisation of proceeds of the Preferential Issue, as certified by the Statutory Auditors of the Company.

Pursuant to Regulation 23(9) of SEBI (LODR) Regulations, 2015, Related Party Transactions on a consolidated basis are considered and approved for the half-year ended September 30, 2026.

The Unaudited Standalone and Consolidated Financial Results of the Company, along with the Limited Review Report for the half-year ended September 30, 2026 and Statement of the Deviation regarding the utilisation of proceeds of the Preferential Issue are enclosed herewith.

In furtherance to the Intimation filed by the Company dated September 28, 2026 the Trading Window for trading in the Securities of the Company, which was closed from October 1, 2026 until 48 hours after the declaration of the Standalone Financial Results, shall be opened after the expiry of forty-eight hours after declaration of the said Results.

The Meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 5:10 P.M.

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:13:37 +05'30'

**Madhusudhan Yadamakanti Reddy**
**Managing Director**
**DIN: 02874260**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

| | Particulars | Half - Year Ended | | | Year Ended | |
|---|---|---|---|---|---|---|
| | | 30-Sep 2026 | 31-Mar 2026 | 30-Sep 2025 | 31-Mar 2026 | 31-Mar 2025 |
| | | Unaudited | Audited | Unaudited | Audited | Audited |
| **I** | **Income** | | | | | |
| (a) | Revenue from Operations | 3,260.00 | 3,259.90 | 966.40 | 4,226.30 | 1,480.99 |
| (b) | Other Income | 0.07 | 0.12 | - | 0.12 | 46.85 |
| | **Total Revenue** | **3,260.07** | **3,260.02** | **966.40** | **4,226.42** | **1,527.84** |
| **II** | **Expenses** | | | | | |
| (a) | Cost of Materials Consumed | 2,907.92 | 2,866.01 | 896.73 | 3,762.74 | 1,347.23 |
| (b) | Purchase of Stock in Trade | - | - | - | - | - |
| (c) | Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods | - | - | - | - | - |
| (d) | Employee Benefit Expenses | 89.60 | 55.80 | 18.29 | 74.09 | 29.50 |
| (e) | Finance Cost | 0.01 | 0.11 | 6.77 | 6.88 | 84.51 |
| (f) | Depreciation and Amortisation Expenses | 20.35 | 21.03 | 7.45 | 28.48 | 10.44 |
| (g) | Other Expenses | 66.26 | 52.36 | 17.78 | 70.14 | 25.58 |
| | **Total Expenses** | **3,084.14** | **2,995.31** | **947.02** | **3,942.33** | **1,497.26** |
| **III** | **Profit / (Loss) Before Exceptional Items and Tax** | **175.93** | **264.71** | **19.38** | **284.09** | **30.58** |
| | Exceptional Items | - | - | - | - | - |
| | **Profit / (Loss) Before Tax** | **175.93** | **264.71** | **19.38** | **284.09** | **30.58** |
| **IV** | **Tax Expense:** | | | | | |
| | (1) Current Tax | 45.91 | 83.20 | 4.63 | 87.83 | 6.95 |
| | (2) Deferred Tax | 1.86 | 3.80 | -0.42 | 3.38 | 1.28 |
| | Profit / (Loss) for the Period from Continuing Operations | **128.16** | **177.71** | **15.17** | **192.88** | **22.35** |
| | Profit / (Loss) from Discontinued Operations | - | - | - | - | - |
| | Tax Expense of Discontinued Operations | - | - | - | - | - |
| | Profit / (Loss) from Discontinued Operations (After Tax) | - | - | - | - | - |
| **V** | **Profit / (Loss) for the Period** | **128.16** | **177.71** | **15.17** | **192.88** | **22.35** |
| | Other Comprehensive Income | - | - | - | - | - |
| | A (i) Items that will not be reclassified to Profit or Loss | - | - | - | - | - |
| | (ii) Income Tax relating to items that will not be reclassified to Profit or Loss | - | - | - | - | - |
| | B (i) Items that will be reclassified to Profit or Loss | - | - | - | - | - |
| | (ii) Income Tax relating to items that will be reclassified to Profit or Loss | - | - | - | - | - |
| | "Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)" | - | - | - | - | - |
| **VI** | **Earnings Per Equity Share – Basic and Diluted** | **0.84** | **1.26** | **0.11** | **1.37** | **0.16** |

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667
Tel No: 040- 79618843 CIN: L24230TG2005PLC046689 GST: 36AACCV1433D1ZR
E-mail: cs@vilinbio.com Website: www.vilinbio.com

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

Notes to Accounts:

1. The above Unaudited Standalone Financial Results for the half-year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on November 14, 2026 and the Statutory Auditors of the Company have issued the Limited Review Report.
2. The Financial results have been prepared in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and Accounting Principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
3. The Company operates in Single Segment hence the segment reporting is not applicable to the company.
4. Previous period figures have been re-classified/ re-grouped wherever considered necessary to confirm to the current period figures.

**For Vilin Bio Med Limited**

**Date: November 14, 2026**
**Place: Hyderabad**

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:14:04 +05'30'

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

## STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. in Lakhs)

| | Particulars | | As at 30-Sep-2026 | As at 31-Mar-2026 |
|---|---|---|---|---|
| | | | (Unaudited) | (Audited) |
| I | **EQUITY AND LIABILITIES** | | | |
| (A) | **Shareholder's Funds** | | | |
| (a) | Share Capital | | 1,525.00 | 1,525.00 |
| (b) | Reserves and Surplus | | 1,440.40 | 1,312.24 |
| (c) | Money received against Share Warrants | | - | - |
| | | | **2,965.40** | **2,837.24** |
| (B) | **Non-Current Liabilities** Long-Term Borrowings Other Long-Term Liabilities Deferred Tax Liabilities (Net) Other Non-Current Liabilities | | | |
| (a) | | | - | - |
| (b) | | | 14.67 | 12.81 |
| (c) | | | - | - |
| (d) | | | - | - |
| | | | **14.67** | **12.81** |
| (C) | **Current Liabilities** Short Term Borrowings Trade Payables | | | |
| (a) | | | 4.41 | 20.59 |
| (b) | - Total Outstanding due to MSMEs | | - | - |
| | - Total Outstanding dues other than MSMs | | 608.28 | 335.50 |
| (c) | Other Current Liabilities | | 224.80 | 206.35 |
| (d) | Short Term Provisions | | 126.58 | 81.73 |
| | | | **964.07** | **644.17** |
| | **Total Equity and Liabilities** | | **3,944.14** | **3,494.22** |
| II | **ASSETS** | | | |
| (A) | **Non-Current Assets** | | | |
| (a) | Property, Plant and Equipment and Intangible Assets | | | |
| | (i) Property, Plant and Equipment | | 305.34 | 286.51 |
| | (ii) Capital work-in-progress | | - | - |
| | (iii) Intangible Assets | | - | - |
| (b) | Non - Current Investments | | 2.00 | - |
| (c) | Deferred Tax Assets (Net) | | - | - |
| (d) | Long Term Loans and Advances | | - | - |
| (e) | Other Non-Current Assets | | 469.41 | 469.41 |
| | | | **776.75** | **755.92** |

**Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034**

**Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667**

**Tel No: 040- 79618843** **CIN: L24230TG2005PLC046689** **GST: 36AACCV1433D1ZR**

**E-mail: cs@vilinbio.com** **Website: www.vilinbio.com**

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

| | | | | |
|---|---|---|---|---|
| (B) | **Current Assets** | | | |
| (a) | Current investments | | - | - |
| (b) | Inventories | | 1,049.22 | 721.53 |
| (c) | Trade receivables | | 1,871.34 | 1,595.62 |
| (d) | Cash and cash equivalents | | 21.52 | 146.99 |
| (e) | Short-term loans and advances | | 57.07 | 43.29 |
| (f) | Other current assets | | 168.24 | 230.87 |
| | | | **3,167.39** | **2,738.30** |
| | **Total Assets** | | **3,944.14** | **3,494.22** |

**Date: November 14, 2026**
**Place: Hyderabad**

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:14:22 +05'30'

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

| STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026 | | |
|---|---|---|
| **Particulars** | **As at 30-Sep-2026** | **As at 31-Mar-2026** |
| | **Unaudited** | **Audited** |
| **Cash Flow from Operating Activities** | | |
| Net Profit Before Tax and Extra-ordinary Items | 175.93 | 284.09 |
| **Adjustment For** | - | - |
| Depreciation | 20.35 | 28.48 |
| Foreign Exchange | - | - |
| Gain or Loss on Sale of Fixed Assets | - | - |
| Gain or Loss on Sale of Investment | - | - |
| Finance Cost | 0.01 | - |
| Dividend Income | - | - |
| Other adjustment of Non-Cash Item | - | - |
| Other adjustment to reconcile Profit | - | - |
| | 20.36 | 28.48 |
| **Adjustment for Working Capital Change** | | |
| Adjustment for Increase/Decrease in Inventories | -327.69 | -280.35 |
| Adjustment for Increase/Decrease in Trade Receivables | -275.72 | -740.11 |
| Adjustment for Increase/Decrease in Other Current Assets | 62.63 | -84.39 |
| Adjustment for Increase/Decrease in Other Non-Current Assets | - | - |
| Adjustment for Increase/Decrease in Short Term Borrowings | - | - |
| Adjustment for Increase/Decrease in Long Term Loans and Advances | - | - |
| Adjustment for Increase/Decrease in Short Term Loans and Advances | -13.78 | 531.29 |
| Adjustment for Increase/Decrease in Trade Payables | 272.78 | 191.61 |
| Adjustment for Increase/Decrease in Other Current Liabilities | 18.45 | 203.97 |
| Adjustment for Provisions | -1.06 | 23.04 |
| **Total Adjustment for Working Capital (B)** | **-264.39** | **-154.94** |
| **Total Adjustment to reconcile Profit (A+B)** | **-244.03** | **-126.46** |
| **Net Cash Flow from (Used in) Operations** | **-68.10** | **157.63** |
| Dividend Received | - | - |
| Interest Received | - | - |
| Interest Paid | - | - |
| Income Tax Paid / Refund | - | -87.83 |
| **Net Cash Flow from (used in) operation before Extra-ordinary Items** | **-68.10** | **69.80** |
| Proceeds from Extra-ordinary Items | - | - |

| | | |
|---|---|---|
| Payment for Extra-ordinary Items | - | - |
| **Net Cash Flow from Operating Activities** | **-68.10** | **69.80** |
| **Cash Flows from Investing Activities** | | |
| Proceeds from Fixed Assets | - | - |
| Proceeds from Investment or Equity Instruments | - | - |
| Purchase of Fixed Assets | -39.18 | -29.68 |
| Purchase of Investments or Equity Instruments | -2.00 | |
| Interest Received | - | - |
| Dividend Received | - | - |
| Cash Receipt from Sale of Interest in Joint Venture | - | - |
| Cash Payment to acquire Interest in Joint Venture | - | - |
| Cash Flow from losing Control of Subsidiaries | - | - |
| Cash Payment for acquiring Control of Subsidiaries | - | - |
| Proceeds from Government Grant | - | - |
| Other Inflow / Outflow of Cash | - | - |
| **Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items** | **-41.18** | **-29.68** |
| Proceeds from Extra Ordinary Items | - | - |
| Payment for Extra Ordinary Item | - | - |
| **Net Cash Flow from (Used in) in Investing Activities** | **-41.18** | **-29.68** |
| **Cash Flows from Financial Activities** | | |
| Proceeds from Issue of Shares | - | 130.00 |
| Proceeds from Issuing shares for security premium | - | 208.00 |
| Proceeds from Issue of Debenture / Bonds / Notes | - | |
| Redemption of Preference Shares | - | - |
| Redemption of Debentures | - | - |
| Proceeds from other Equity Instruments | - | - |
| Proceeds from Borrowing | | |
| Repayment of Borrowing | -16.18 | -236.74 |
| Dividend Paid | - | - |
| Interest Paid | -0.01 | |
| Income Tax Paid / Refund | - | - |
| **Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items** | **-16.19** | **101.26** |
| Proceeds from Extra-ordinary Items | - | - |
| Payment for Extra-ordinary Items | - | - |
| **Net Cash Flow from (Used in) in Financial Activities** | **-16.19** | **101.26** |
| **Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes** | **-125.47** | **141.38** |
| Effect of Exchange Rate change on Cash and Cash Equivalents | - | - |

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

| | | |
|---|---|---|
| **Net Increase (Decrease) in Cash and Cash Equivalents** | **-125.47** | **141.38** |
| Cash and Cash Equivalents at beginning of period | 146.99 | 5.61 |
| **Cash and Cash Equivalents at end of period** | **21.52** | **146.99** |

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:14:45 +05'30'

**Date: November 14, 2026**
**Place: Hyderabad**

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

**Independent Auditor's Limited Review Report on Half-Yearly Standalone Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To**
**The Board of Directors**
**Vilin Bio Med Limited**

We have reviewed the accompanying Unaudited Standalone Financial Results ('the Statement') of Vilin Bio Med Limited ('the Company') for the half-year ended September 30, 2026, which comprise the Statement of Assets and Liabilities and the Statement of Cash Flows as at September 30, 2026, Statement of Profit and Loss, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").

**Management's Responsibility**

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standard 25, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other Accounting Principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

**Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for Financial and Accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an Audit Opinion.



Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standards specified under Section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 09655S




Girdhari Lal Toshniwal
Partner
M. No. 205140
UDIN: 26205140EALRKA3457

Date: 14/11/2026
Place: Hyderabad

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs)

| | Particulars | Half - Year Ended | | | Year Ended | |
|---|---|---|---|---|---|---|
| | | 30-Sep 2026 | 31-Mar 2026 | 30-Sep 2025 | 31-Mar 2026 | 31-Mar 2025 |
| | | Unaudited | Audited | Unaudited | Audited | Audited |
| **I** | **Income** | | | | | |
| (a) | Revenue from Operations | 3,260.00 | 3,259.90 | 966.40 | 4,226.30 | 1,480.99 |
| (b) | Other Income | 0.07 | 0.12 | - | 0.12 | 46.85 |
| | **Total Revenue** | **3,260.07** | **3,260.02** | **966.40** | **4,226.41** | **1,527.84** |
| **II** | **Expenses** | | | | | |
| (a) | Cost of Materials Consumed | 2,907.92 | 2,866.01 | 896.73 | 3,762.74 | 1,347.23 |
| (b) | Purchase of Stock in Trade | - | - | - | - | - |
| (c) | Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods | - | - | - | - | - |
| (d) | Employee Benefit Expenses | 89.60 | 55.80 | 18.29 | 74.09 | 29.50 |
| (e) | Finance Cost | 0.02 | 0.11 | 6.77 | 6.88 | 84.51 |
| (f) | Depreciation and Amortisation Expenses | 20.35 | 21.03 | 7.45 | 28.48 | 10.44 |
| (g) | Other Expenses | 66.65 | 52.36 | 17.78 | 70.14 | 25.58 |
| | **Total Expenses** | **3,084.54** | **2,995.31** | **947.02** | **3,942.33** | **1,497.26** |
| **III** | **Profit / (Loss) Before Exceptional Items and Tax** | **175.53** | **264.71** | **19.38** | **284.09** | **30.58** |
| | Exceptional Items | - | - | - | - | - |
| | Profit / (Loss) Before Tax | **175.53** | 264.71 | 19.38 | **284.09** | **30.58** |
| **IV** | **Tax Expense:** | | | | | |
| | (1) Current Tax | 45.81 | 83.20 | 4.63 | 87.83 | 6.95 |
| | (2) Deferred Tax | 1.86 | 3.80 | -0.42 | 3.38 | 1.28 |
| | Profit / (Loss) for the Period from Continuing Operations | **127.86** | **177.71** | **15.17** | **192.88** | **22.35** |
| | Profit / (Loss) from Discontinued Operations | - | - | - | - | - |
| | Tax Expense of Discontinued Operations | - | - | - | - | - |
| | Profit / (Loss) from Discontinued Operations (After Tax) | - | - | - | - | - |
| **V** | **Profit / (Loss) for the Period** | **127.86** | **177.71** | **15.17** | **192.88** | **22.35** |
| | Other Comprehensive Income | - | - | - | - | - |
| | A (i) Items that will not be reclassified to Profit or Loss | - | - | - | - | - |
| | (ii) Income Tax relating to items that will not be reclassified to Profit or Loss | - | - | - | - | - |
| | B (i) Items that will be reclassified to Profit or Loss | - | - | - | - | - |
| | (ii) Income Tax relating to items that will be reclassified to Profit or Loss | - | - | - | - | - |
| | "Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period) | - | - | - | - | - |
| **VI** | **Earnings Per Equity Share - Basic and Diluted** | **0.84** | **1.26** | **0.11** | **1.37** | **0.16** |

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

**Notes to Accounts:**

1. The above Unaudited Consolidated Financial Results for the half-year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on November 14, 2026 and the Statutory Auditors of the Company have issued the Limited Review Report.
2. The Financial results have been prepared in accordance with applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and Accounting Principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
3. During the period the company has incorporated two subsidiaries namely M/s. Axia Pharma Private Limited incorporated on July 16, 2026 and M/s. Vilo Speciality Pharma Private Limited incorporated on July 23, 2026. The consolidated financial statements have been presented for half year ended September 30, 2026 while the remaining financial results pertains solely to Vilin Bio Med Limited.
4. The Company operates in Single Segment hence the segment reporting is not applicable to the company.
5. Previous period figures have been re-classified/ re-grouped wherever considered necessary to confirm to the current period figures.

**Date: November 14, 2026**
**Place: Hyderabad**

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:15:15 +05'30'

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

**STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026**

(Rs. in Lakhs)

| | Particulars | | As at 30-Sep-2026 | As at 31-Mar-2026 |
|---|---|---|---|---|
| | | | (Unaudited) | (Audited) |
| I | **EQUITY AND LIABILITIES** | | | |
| (A) | **Shareholder's Funds** | | | |
| (a) | Share Capital | | 1,525.00 | 1,525.00 |
| (b) | Reserves and Surplus | | 1,440.10 | 1,312.24 |
| (c) | Money received against Share Warrants | | - | - |
| | | | **2,965.10** | **2,837.24** |
| (B) | **Non-Current Liabilities** | | | |
| (a) | Long-Term Borrowings | | - | - |
| (b) | Other Long-Term Liabilities | | - | - |
| (c) | Deferred Tax Liabilities (Net) | | 14.67 | 12.81 |
| (d) | Other Non-Current Liabilities | | - | - |
| | | | | |
| (C) | **Current Liabilities** | | | |
| (a) | Short Term Borrowings | | 4.41 | 20.59 |
| (b) | Trade Payables | | | |
| | - Total Outstanding due to MSMEs | | - | - |
| | - Total Outstanding dues other than MSMs | | 607.94 | 335.50 |
| (c) | Other Current Liabilities | | 224.80 | 206.35 |
| (d) | Short Term Provisions | | 126.48 | 81.73 |
| | | | **963.63** | **644.17** |
| | **Total Equity and Liabilities** | | **3,943.40** | **3,494.22** |
| II | **ASSETS** | | | |
| (A) | **Non-Current Assets** | | | |
| (a) | Property, Plant and Equipment and Intangible Assets | | | |
| | (i) Property, Plant and Equipment | | 305.34 | 286.51 |
| | (ii) Capital work-in-progress | | | |
| | (iii) Intangible Assets | | | |
| (b) | Non - Current Investments | | | |
| (c) | Deferred Tax Assets (Net) | | | |
| (d) | Long Term Loans and Advances | | | |
| (e) | Other Non-Current Assets | | 469.41 | 469.41 |

| | | | | |
|---|---|---|---|---|
| | | | **774.75** | **755.92** |
| (B) | **Current Assets** | | | |
| (a) | Current investments | | - | - |
| (b) | Inventories | | 1,049.22 | 721.53 |
| (c) | Trade Receivables | | 1,871.34 | 1,595.62 |
| (d) | Cash and Cash Equivalents | | 22.78 | 146.99 |
| (e) | Short Term Loans and Advances | | 57.07 | 43.29 |
| (f) | Other Current Assets | | 168.24 | 230.87 |
| | | | **3,168.65** | **2,738.30** |
| | **Total Assets** | | **3,943.40** | **3,494.22** |

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY

Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:15:34 +05'30'

**Date: November 14, 2026**
**Place: Hyderabad**

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

VILIN BIO MED

One-Stop Hub for all Pharmaceutical Solutions

| CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026 | | |
|---|---|---|
| **Particulars** | **As at 30-Sep-2026** | **As at 31-Mar-2026** |
| | **Unaudited** | **Audited** |
| **Cash Flow from Operating Activities** | | |
| Net Profit Before Tax and Extra-ordinary Items | 175.53 | 284.09 |
| **Adjustment For** | - | - |
| Depreciation | 20.35 | 28.48 |
| Foreign Exchange | - | - |
| Gain or Loss on Sale of Fixed Assets | - | - |
| Gain or Loss on Sale of Investment | - | - |
| Finance Cost | 0.02 | - |
| Dividend Income | - | - |
| Other adjustment of Non-Cash Item | - | - |
| Other adjustment to reconcile Profit | - | - |
| | **20.37** | **28.48** |
| **Adjustment for Working Capital Change** | | |
| Adjustment for Increase/Decrease in Inventories | -327.69 | -280.35 |
| Adjustment for Increase/Decrease in Trade Receivables | -275.72 | -740.11 |
| Adjustment for Increase/Decrease in Other Current Assets | 62.63 | -84.39 |
| Adjustment for Increase/Decrease in Other Non-Current Assets | - | - |
| Adjustment for Increase/Decrease in Short Term Borrowings | - | - |
| Adjustment for Increase/Decrease in Long Term Loans and Advances | - | - |
| Adjustment for Increase/Decrease in Short Term Loans and Advances | -13.78 | 531.29 |
| Adjustment for Increase/Decrease in Trade Payables | 272.44 | 191.61 |
| Adjustment for Increase/Decrease in Other Current Liabilities | 18.45 | 203.97 |
| Adjustment for Provisions | -1.06 | 23.04 |
| **Total Adjustment for Working Capital (B)** | **-264.73** | **-154.94** |
| **Total Adjustment to reconcile Profit (A+B)** | **-244.36** | **-126.46** |
| **Net Cash Flow from (Used in) Operations** | **-68.83** | **157.63** |
| Dividend Received | - | - |
| Interest Received | - | - |
| Interest Paid | - | - |

| | | |
|---|---|---|
| Income Tax Paid / Refund | - | -87.83 |
| **Net Cash Flow from (used in) operation before Extra-ordinary Items** | **-68.83** | **69.80** |
| Proceeds from Extra-ordinary Items | - | - |
| Payment for Extra-ordinary Items | - | - |
| **Net Cash Flow from Operating Activities** | **-68.83** | **69.80** |
| **Cash Flows from Investing Activities** | | |
| Proceeds from Fixed Assets | - | - |
| Proceeds from Investment or Equity Instruments | - | - |
| Purchase of Fixed Assets | -39.18 | -29.68 |
| Purchase of Investments or Equity Instruments | - | |
| Interest Received | - | - |
| Dividend Received | - | - |
| Cash Receipt from Sale of Interest in Joint Venture | - | - |
| Cash Payment to acquire Interest in Joint Venture | - | - |
| Cash Flow from losing Control of Subsidiaries | - | - |
| Cash Payment for acquiring Control of Subsidiaries | - | - |
| Proceeds from Government Grant | - | - |
| Other Inflow / Outflow of Cash | - | - |
| **Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items** | **-39.18** | **-29.68** |
| Proceeds from Extra Ordinary Items | - | - |
| Payment for Extra Ordinary Item | - | - |
| **Net Cash Flow from (Used in) in Investing Activities** | **-39.18** | **-29.68** |
| **Cash Flows from Financial Activities** | | |
| Proceeds from Issue of Shares | - | 130.00 |
| Proceeds from Issuing shares for security premium | - | 208.00 |
| Proceeds from Issue of Debenture / Bonds / Notes | - | |
| Redemption of Preference Shares | - | - |
| Redemption of Debentures | - | - |
| Proceeds from other Equity Instruments | - | - |
| Proceeds from Borrowing | | |
| Repayment of Borrowing | -16.18 | -236.74 |
| Dividend Paid | - | - |
| Interest Paid | -0.02 | |
| Income Tax Paid / Refund | - | - |
| **Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items** | **-16.20** | **101.26** |
| Proceeds from Extra-ordinary Items | - | - |
| Payment for Extra-ordinary Items | - | - |
| **Net Cash Flow from (Used in) in Financial Activities** | **-16.20** | **101.26** |

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

| | | |
|---|---|---|
| **Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes** | **-124.21** | **141.38** |
| Effect of Exchange Rate change on Cash and Cash Equivalents | - | - |
| **Net Increase (Decrease) in Cash and Cash Equivalents** | **-124.21** | **141.38** |
| Cash and Cash Equivalents at beginning of period | 146.99 | 5.61 |
| **Cash and Cash Equivalents at end of period** | **22.78** | **146.99** |

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:16:02 +05'30'

**Madhusudhan Y Reddy**
**Managing Director**
**DIN: 02874260**

**Date: November 14, 2026**
**Place: Hyderabad**

**Independent Auditor's Limited Review Report on Half-Yearly Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To**
**The Board of Directors**
**Vilin Bio Med Limited**

We have reviewed the accompanying Unaudited Consolidated Financial Results ('the Statement') of Vilin Bio Med Limited ('the Company') for the half-year ended September 30, 2026, which comprise the Statement of Assets and Liabilities and the Statement of Cash Flows as at September 30, 2026, Statement of Profit and Loss, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").

**Management's Responsibility**

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standard 25, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other Accounting Principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

**Auditor's Responsibility**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for Financial and Accounting matters, and applying analytical and other review procedures. A Review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143 (10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit Opinion.

The Statement includes the results of the Subsidiaries listed below:

1. VILO SPECIALITY PHARMA PRIVATE LIMITED
2. AXIA PHARMA PRIVATE LIMITED

PPKG & CO. HYDERABAD Chartered Accountants

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Recognition and Measurement Principles laid down in Accounting Standards specified under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereafter and other Accounting Principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

These Consolidated Financials include the Financials of M/s Axia Pharma Private Limited in which M/s Vilin Bio Med Limited, the Holding Company, holds 100% stake. M/s Axia Pharma Private Limited has been recently incorporated and presently has not commenced any business activity.

These Consolidated Financials include the financials of M/s Vilo Speciality Pharma Private Limited M/s Vilin Bio Med Limited, the Holding Company, holds 100% stake. M/s Vilo Speciality Pharma Private Limited has been recently incorporated and presently has not commenced any business activity.

For PPKG And CO
Chartered Accountants
FRN: 09655S

PPKG & CO. HYDERABAD Chartered Accountants

Girdhari Lal Toshniwal
Partner
M. No. 205140
UDIN: 26205140HCGZUE8692

Date: 14/11/2026
Place: Hyderabad

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

November 14, 2026

**To**
**The Listing Department**
**National Stock Exchange of India Limited**
**Exchange Plaza, Plot C-1, Block- G**
**Bandra Kurla Complex, Bandra (East)**
**Mumbai – 400051**

**NSE Scrip: VILINBIO**

**Sub: Statement of Deviation and Variation for Utilization of Funds Raised through Preferential Issue**

Dear Sir / Madam

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that there have been no Deviation (s) or Variation (s) in the utilisation of Proceeds raised through Preferential Issue; and proceeds are utilised as per the Objects stated in the Offer Document.

We enclose herewith the Statement of Deviation or Variation for half-year ended 30 September, 2026 as reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective Meeting held on Saturday, November 14, 2026.

Kindly take the same on record.

**For Vilin Bio Med Limited**

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.11.14 17:16:25 +05'30'

**Madhusudhan Yadamakanti Reddy**
**Managing Director**
**DIN: 02874260**

| | |
|---|---|
| Name of Listed Entity | Vilin Bio Med Limited |
| Mode of Fund Raising | Preferential Issue |
| Date of Raising Funds | March 4, 2026 |
| Amount Raised | Rs.338.00 Lakhs |
| Report filed for half-year ended | September 30, 2026 |
| Monitoring Agency | NA |
| Monitoring Agency Name | NA |
| Is there a Deviation / Variation in use of Funds raised ? | No |
| Whether any approval is required to vary the Objects of the Issue stated in the Prospectus / Offer Document? | No |
| If yes, details of the approval so required? | NA |
| Date of Approval | NA |
| Explanation for the Deviation / Variation | NA |
| Comments of the Audit Committee after review | Nil |
| Comments of the Auditors, if any | Nil |
| Objects for which Funds have been raised and wherethere has been a deviation, in the following table | No Deviation |

PPKG & CO. HYDERABAD Chartered Accountants

| Original Object | Modified Object | Original Allocation (Rs. in Lakhs) | Modified Allocation | Funds Utilised (Rs. in Lakhs) | Balance Amount (Rs. in Lakhs) | Amount of Deviation / Variation for the applicable Object |
|---|---|---|---|---|---|---|
| Working Capital | NA | 327.00 | NA | 327.00 | 0.00 | NA |
| Issue Expenses | NA | 11.00 | NA | 11.00 | 0.00 | NA |
| Total | | 338.00 | | 338.00 | 0.00 | |

Deviation could mean:

(a) Deviation in the Objects or purposes for which the Funds have been raised
(b) Deviation in the amount of Funds actually utilised as against what was originally disclosed.
(c) Change in terms of Contract referred to the Fund-raising document i.e., Prospectus / Letter of Offer, etc.

For PPKG & Co
Chartered Accountants
FRN: 009655S

PPKG & CO. HYDERABAD Chartered Accountants

Girdhari lal Toshinwal
Partner
M. No. 205140
UDIN: 26205140TVFCMT8860

Date : November 14, 2026
Place: Hyderabad